We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 28, 2021

ECHELON-2: 5-Year Results of Brentuximab Vedotin + Chemotherapy for CD30+ Peripheral T-Cell Lymphoma

Annals of Oncology

 

Additional Info

Annals of Oncology
The ECHELON-2 Trial: 5-year results of a randomized, phase 3 study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma∗
Ann. Oncol 2021 Dec 15;[EPub Ahead of Print], S Horwitz, OA O’Connor, B Pro, et al

Further Reading